CELZ-201-DDT
PreclinicalSmall molecule
CELZ-201-DDT is one of 39 small molecule programs targeting Back pain. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Back Pain
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Toradol
RocheApproved
Lexapro
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Tylenol
KKenvue Brands
Approved
Ultram
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Back pain1 trial
Chronic Low Back Pain1 trial
A Double-blinded, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Effectiveness of CELZ-201-DDT Administered by Intramuscular Injection for the Treatment of Chronic Lower Back Pain in Patients With Degenerative Disc Disease
Active, not recruiting·CCreative Medical Technology Holdings Inc·Preclinical·NCT06053242·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CELZ-201-DDT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details